63429-99-2Relevant academic research and scientific papers
USP8 inhibitor, preparation method and applications thereof
-
Paragraph 0061-0064, (2020/06/02)
The invention discloses a USP8 inhibitor, a preparation method and applications thereof, belongs to the field of medicinal chemistry, and particularly relates to a class of USP8 inhibitors (I) containing substituted thiourea or substituted guanidine derivatives, and a preparation method thereof. According to the invention, the results of biological experiments prove that the compound has good USP8inhibitory activity and cell activity and can be used for treating diseases such as malignant tumors and the like.
Discovery of novel USP8 inhibitors via Ubiquitin-Rho-110 fluorometric assay based high throughput screening
Bian, Jinlei,Chen, Kaixian,Ding, Hong,Han, Jie,Jiang, Hualiang,Li, Zhiyu,Luo, Cheng,Ma, Zengyi,Tian, Yucheng,Wang, Jubo,Xu, Xi,Yu, Liang,Zhang, Qilin,Zhang, Yichao,Zhao, Yao
, (2020/06/01)
USP8, one member of deubiquitinating enzymes (DUBs) families, maintains the ubiquitination level of EGFR and regulates the downstream signaling pathways. The deregulation of USP8 has been implicated in many human diseases, especially in cancer. Therefore, USP8 has been identified as a promising target for drug design. Herein, via high throughput screening based on Ubiquitin-rhodamine-110 (Ubiquitin-Rho-110) fluorometric activity assay, we discovered a novel inhibitor DC-U43. By structure optimization, DC-U43-10 reached a half-maximal inhibitory concentration (IC50) value of 2.6 ± 1.1 μM and exhibited 10-fold selectivity against USP7. The binding between DC-U43-10 and USP8 was validated by surface plasmon resonance (SPR) assay with a KD value of 10.5 ± 3.7 μM. It also inhibited the colony formation of H1975 cells. Hence, DC-U43-10 represents a kind of USP8 inhibitors with novel scaffold and has broad prospects for being a probe for USP8-related academic and clinical research.
